ACTU
Actuate Therapeutics IncHealthcare·Biotechnology
$2.02
$48M market cap
Revenue
$0.0M
Free Cash Flow
$-8.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate The
2-Year Price History
$2.38-72.6%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -5.7 | -5.7 | -5.6 | -5.0 | -5.0 | -0.0 | 8.1 | 0.4 | 23.5 | <-999% | -1127.2x | -- |
| Act | 2025-Q4 | 0.0 | -4.7 | -4.7 | -4.6 | -3.7 | -3.7 | -0.0 | 13.2 | 0.4 | 23.3 | -629.3% | -926.0x | -- |
Valuation & Metrics
Market Stats
Price$2.02
Market Cap$48M
Enterprise Value$41M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-18.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-10.2M
Free Cash Flow$-8.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-3132.5%
WC Change % Rev0.0%
Interest Coverage-1026.6x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.0M
Days to Cover3.8
Change (vs Prior)+3.6%
Need at least 2 settlement dates for chart
Employees
Headcount10
Revenue / Employee$0
Gross Profit / Employee$0
Cash Runway
11.2months
CRITICAL
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
58.2%(-59.6% YoY)
52 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.3%(+4.9% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.0%(-0.6% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| BIOS Capital Management, LP | $27.5M | $7.94 | +$0 | +$428K | +6.7% | $52.9M |
| Voss Capital, LLC | $4.7M | $5.58 | +$1.2M | +$4.3M | -0.8% | $1.75B |
| BlackRock, Inc.Passive | $1.2M | $6.26 | −$13K | +$1.1M | -0.2% | $5.69T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.1M | $2.74 | +$1.1M | +$1.1M | — | $4.04T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $626K | $6.06 | +$56K | +$534K | +2.3% | $1.61T |
| Connective Capital Management, LLC | $310K | $2.74 | +$310K | +$310K | +2.5% | $121M |
| Palogic Value Management, L.P. | $274K | $2.74 | +$274K | +$274K | -2.7% | $226M |
| NORTHERN TRUST CORPPassive | $268K | $6.46 | −$10K | +$121K | -0.2% | $755.34B |
| Texas Capital Bank Wealth Management Services Inc | $259K | $6.12 | +$0 | +$259K | -0.1% | $1.68B |
| STATE STREET CORPPassive | $181K | $5.78 | +$27K | +$181K | -0.2% | $2.89T |
| VANGUARD FIDUCIARY TRUST COPassive | $172K | $2.74 | +$172K | +$172K | — | $395.83B |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $152K | $2.74 | +$152K | +$152K | — | $1.91T |
| ABS Direct Equity Fund LLC | $137K | $3.19 | +$119K | +$137K | -3.8% | $131M |
| Rock Creek Group, LP | $108K | $4.61 | +$48K | +$108K | -3.1% | $988M |
| DEUTSCHE BANK AG\ | $100K | $4.11 | +$74K | +$100K | -0.3% | $302.17B |
| SFMG, LLC | $90K | $5.05 | +$36K | +$60K | +0.1% | $1.46B |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $86K | $4.84 | +$35K | +$77K | -0.0% | $162.09B |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $85K | $6.12 | +$0 | +$85K | -2.3% | $4.93B |
| AQR CAPITAL MANAGEMENT LLC | $74K | $2.74 | +$74K | +$74K | -0.2% | $218.19B |
| ROYAL BANK OF CANADA | $61K | $6.87 | −$36K | +$10K | -0.2% | $526.36B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-10.90%
avg per quarter
Holders (ex-self)
+5.22%
excl. this stock
Buyers (this Q)
-0.54%
27 buyers · $0.00B in
Sellers (this Q)
-0.03%
13 sellers · $0.00B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+25.5%
how holders react when this stock falls
On quiet Qs
+11.5%
−10% to +10% baseline
On rallies (+10%+)
-0.0%
how they react when this stock rises
Holders' portfolio flow this Q
+1.8%
inflows — adds are organic
Sellers' portfolio flow this Q
+1.4%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
+0.5%
Holder mid (any stock)
+1.1%
Holder rally (any stock)
-0.0%
Biggest decreases this quarter
JANE STREET GROUP, LLCexited−$102KSUSQUEHANNA INTERNATIONAL GROUP, LLPexited−$63KNORTHWESTERN UNIVERSITYexited−$43KROYAL BANK OF CANADA−$36Kα-0.2GOLDMAN SACHS GROUP INC−$27Kα-0.2BlackRock, Inc.−$13Kα-0.2NORTHERN TRUST CORP−$10Kα-0.2CALIFORNIA STATE TEACHERS RETIREMENT SYSTEMexited−$4KAMALGAMATED BANKexited−$2K
New buyers this quarter
Top-5 holders · 92.6%
BIOS Capital Management, LP--
Voss Capital, LLC--
BlackRock, Inc.--
VANGUARD CAPITAL MANAGEMENT LLC--
GEODE CAPITAL MANAGEMENT, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
BIOS Capital Management, LP10.0MVoss Capital, LLC1.7MAWM Investment Company, Inc.—Long Corridor Asset Management Ltd—Texas Capital Bank Wealth Management Services Inc95KConnective Capital Management, LLC113KPalogic Value Management, L.P.100KROYAL BANK OF CANADA22KBARCLAYS PLC2KNORTHWESTERN UNIVERSITY—
Analyst Coverage
Analyst Coverage
Analyst Ratings
1
Buy: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$3.00M
3 txns · 3 insiders · 428,568 sh
Sells ($, 12mo)
$1.62M
1 txn · 1 insider · 280,000 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | SELL | THOMSON TODD S | director, 10 percent owner: | 280,000 | $5.80 | $1.62M | $5.25M |
| 2025-06-27 | BUY | Bios Equity COF, LP | director, 10 percent owner: | 142,856 | $7.00 | $1000K | $1.37M |
| 2025-06-27 | BUY | Fletcher Aaron G.L. | director, 10 percent owner: | 142,856 | $7.00 | $1000K | $1.37M |
| 2025-06-27 | BUY | Kreis Leslie W. | director, 10 percent owner: | 142,856 | $7.00 | $1000K | $1.37M |
Order Flow (FINRA, ~3w lag)
48.2%retail-1.5pp
8.5%dark+5.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Actuate Therapeutics: A Bio-Tech Dilution Machine Fighting the Clock
Overall Risk
8/10
Fraud
4/10
Dilution
9/10
Insolvency
9/10
Earnings Overstated
3/10
Hidden Liabilities
4/10
Legal
3/10
Audit Warnings
9/10
Hidden Upside
3/10
Contextually Acceptable
3/10